Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial

Blood

Volumn 119, Issue 22, 2012, Pages 5104-5110

  Lepretre, Stephane ^a   Aurran, Therese ^b   Mahé, Beatrice ^c   Cazin, Bruno ^d   Tournilhac, Olivier ^e   Maisonneuve, Herve ^f   Casasnovas, Olivier ^g   Delmer, Alain ^h   Leblond, Veronique ⁱ   Royer, Bruno ^j   Corront, Bernadette ^k   Chevret, Sylvie ^l   Delépine, Roselyne ^m   Vaudaux, Sandrine ^a   Van Neste, Eric Den ⁿ   Béné, Marie Christine ^o   Letestu, Remi ^p   Cymbalista, Florence ^p   Feugier, Pierre ^q  

^a CENTRE HENRI BECQUEREL   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^f CENTRE HOSPITALIER   (France)

^g DIJON UNIVERSITY HOSPITAL   (France)

^h REIMS UNIVERSITY HOSPITAL   (France)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^j AMIENS UNIVERSITY HOSPITAL   (France)

^k Centre Hospitalier de la Region d'Annecy   (France)

^l SAINT LOUIS HOSPITAL   (France)

^m UNIVERSITY HOSPITAL OF TOURS   (France)

ⁿ CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^o UNIVERSITÉ DE LORRAINE   (France)

^p AVICENNE HOSPITAL   (France)

^q UNIVERSITY HOSPITAL OF NANCY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART FAILURE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCORMYCOSIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SEPTIC SHOCK; TREATMENT RESPONSE;

EID: 84861795688     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-07-365437     Document Type: Article

References (16)

1. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-74.
2. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukaemia. J Clin Oncol. 2007;25(35):5616-5623.
3. Elter T, Borchmann P, Schulz H, et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukaemia: results of a phase II trial. J Clin Oncol. 2005;23(28): 7024-7031.
4. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990-4997.
5. Fortin M, Hudon C, Dubois MF, Almirall J, Lapointe L, Soubhi H: Comparative assessment of three different indices of multimorbidity for studies on health-related quality of live. Health Qual Life Outcomes. 2005;3:74.
6. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079-4088.
7. Rawstron AC, Villamor N, Ritgen M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007;21(5):956-964.
8. Engert A, Gercheva L, Pilipenko G, et al. Overall survival advantage and acceptable safety profile with fludarabine in combination with alemtuzumab (FluCam) in previously treated patients with advanced stage chronic lymphocytic leukemia [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116:919.
9. Elter T, James R, Stilgenbauer S, et al. Chemoimmuno- therapy with fludarabine, cyclophosphamide and alemtuzumab (FC-Cam) in patients with relapsed or genetic high-risk CLL: final analysis of the CLL2L Trial of the German CLL Study Group [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114:209.
10. Badoux XC, Keating MJ, Wang X, et al. Cyclophosphomide, fludarabine, rituximab and alemtuzumab (CFAR) as salvage therapy for heavily pre-treated patients with Chronic Lymphocytic Leukemia (CLL). Blood. 2011;118(8):2085-2093.
11. Parikh SA, Keating M, O'Brien S, et al. Frontline combined chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab and rituximab (CFAR) in high-risk chronic lymphocytic leukemia. Blood. 2011;118(8):2062-2068.
12. Montillo M, Tedeschi A, Petrizzi VB, et al. An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab (FCC) in relapsed/ refractory patients with B-cell chronic lymphocytic leukemia. Blood. 2011;118(15):4079- 4085.
13. Geisler H, Van't Veer MB, Van Putten M, et al. Immunochemotherapy with low-dose subcutaneous alemtuzumab (A) plus oral fludarabine and cyclophosphamide (FC) is safe and induces more and deeper complete remissions in untreated patients with high-risk chronic lymphocytic leukemia (CLL) than chemotherapy with FC alone. An early analysis of the randomized phase-III HOVON68 CLL Trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2011; 118:290.
14. Rossi JF, van Hoof A, de Boeck K, et al Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2004;22(7):1260-1267.
15. Boogaerts MA, Van Hoof A, Catovsky D, et al. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2001;19(22):4252-4258.
16. Cazin B, Divine M, Lepretre S, et al. High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia. Br J Haematol. 2008;143(1):54-59.